
Response To Alexandros Contra Me On Ivermectin
Astral Codex Ten Podcast
00:00
Is It Possible to Re-Analyze a Study in Brazil?
Ivan Meckton does worst in studies of intermediate clinical endpoints, link in post, hospitalisation, ICU admission, recovery time. Stronger-Loydy's hypothesis tries to provide it. But I erred on my earlier post by holding it up as THE explanation for a large and heterogeneous group of studies which were mostly looking at endpoints other than mortality. It does best in studies of viral clearance rate and mortality. Viral clearance rate is a weak pre-clinical end point - not that interesting unless it affects later clinical outcomes. Many drugs change secondary endpoints but fail to change the things we care about. A parent positive results of Ivan Meckton here require
Transcript
Play full episode